Compounds > pamaqueside
Page last updated: 2024-11-12

pamaqueside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pamaqueside: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9918516
CHEMBL ID505268
SCHEMBL ID126856
MeSH IDM0261481

Synonyms (25)

Synonym
pamaqueside
D05344
pamaqueside (usan/inn)
150332-35-7
CHEMBL505268
cp-148623
cp-148,623
11-ketotigenin cellobioside
spirostan-11-one, 3-((4-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)oxy)-, (3beta,5alpha,25r)-
cp 148623
pamaqueside [usan:inn]
unii-l1y3wkm9wu
l 165313
11-oxo-(25r)-5alpha-spirostan-3beta-yl 4-o-beta-d-glucopyranosyl-beta-d-glucopyranoside
l1y3wkm9wu ,
spirostan-11-one, 3-((4-o-.beta.-d-glucopyranosyl-.beta.-d-glucopyranosyl)oxy)-, (3.beta.,5.alpha.,25r)-
11-oxo-(25r)-5.alpha.-spirostan-3.beta.-yl 4-o-.beta.-d-glucopyranosyl-.beta.-d-glucopyranoside
pamaqueside [who-dd]
pamaqueside [usan]
pamaqueside [inn]
SCHEMBL126856
spirostan-11-one,3-[(4-o-b-d-glucopyranosyl-b-d-glucopyranosyl)oxy]-,(3b,5a,25r)-
(1s,2s,4s,5'r,6r,7s,8r,9s,12s,13s,16s,18s)-16-[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2
Q27282597
AKOS040746199

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pamaqueside-treated rabbits exhibited a more rapid decline in plasma cholesterol concentrations than control animals fed a cholesterol-free diet, indicating that the compound also inhibited the absorption of biliary cholesterol."( Comparison of synthetic saponin cholesterol absorption inhibitors in rabbits: evidence for a non-stoichiometric, intestinal mechanism of action.
Bangerter, FW; Chandler, CE; DeNinno, MP; Inskeep, PB; McCarthy, PA; Morehouse, LA; Pettini, JL; Savoy, YE; Sugarman, ED; Wilkins, RW; Wilson, TC; Woody, HA; Zaccaro, LM, 1999)		1.02

Dosage Studied

ExcerptRelevanceReference
" This conclusion was confirmed by studies in which intestinal brush borders were isolated from hamsters dosed with (3)H-cholesterol in the presence or absence of L-166,143."( A target for cholesterol absorption inhibitors in the enterocyte brush border membrane.
Chao, YS; Detmers, PA; Hernandez, M; Kim, D; Lisnock, JM; Montenegro, J; Patel, S; Pikounis, B; Sparrow, C; Steiner, M; Wright, SD, 2000)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID22991Pharmacokinetic parameter volume was determined in fed Beagle dogs after iv administration of 1.5 mg/kg1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster.
AID14730Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster.
AID19123Pharmacokinetic parameter half-life was determined in fed Beagle dogs after iv administration of 1.5 mg/kg1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster.
AID14459Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster.
AID402083Reduction in serum LDL-cholesterol level in normolipidemic human at 300 mg administered twice daily for 2 weeks1998Journal of natural products, Aug, Volume: 61, Issue:8
Recent natural products based drug development: a pharmaceutical industry perspective.
AID17999Bioavailability in fed Beagle dogs at a dose of 500 mg/kg1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster.
AID16273Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster.
AID402084Inhibition of fractional cholesterol absorption in normolipidemic human at 300 mg administered twice daily for 2 weeks1998Journal of natural products, Aug, Volume: 61, Issue:8
Recent natural products based drug development: a pharmaceutical industry perspective.
AID84836Effective dose against cholesterol absorption determined by hepatic 3H content after 3 hr of administration to hamsters1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (72.73)18.2507
2000's3 (27.27)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.60 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews2 (18.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		210isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		210delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
lecimibide
[no description available]		210
devazepide
Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding.. devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.		3.09101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
asperlicin
asperlicin: cholecystokinin antagonist; isolated from Aspergillus alliaceus; structure given in first source		3.0910
l 365260
L 365260: a CCK-B antagonist; structure given in first source; potent & selective CCK-B & gastrin receptor ligand; L 365260 and L 365346 are (R)- and (S)-stereoisomers, respectively		3.0910benzodiazepine
beta-escin
[no description available]		6.19101
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		210
tiqueside
tiqueside: reduces intestinal cholesterol absorption with little change in HDL-cholesterol levels & without interfering with enterohepatic bile acid recirculation ; structure given in first source		2.6930
ConditionIndicatedRelationship StrengthStudiesTrials
Elevated Cholesterol
[description not available]		04.0731
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		04.0731
Hyperlipemia
[description not available]		02.9210
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		02.9210